The app that went viral for telling users when they'd die now wants to sell them a few extra years.
Death Clock—yes, that Death Clock, the morbid little program that accumulated over a million downloads by offering AI-generated mortality predictions—has pivoted. Hard. On February 2, 2026, the company unveiled Life Lab, a blood testing service that layers biomarker tracking and preventive health guidance atop its original death-date calculator. The move transforms what began as a curiosity into something closer to a longevity platform, placing the startup squarely in competition with Function Health, Levels, and the expanding universe of consumer diagnostics companies betting big on mass-market blood work.
It's a peculiar trajectory. But perhaps that's the point.
"We've got name recognition," founder Brent Franson acknowledged in a recent interview with The Spoon. What Death Clock didn't have, until now, was a clear path from viral novelty to sustainable business. Life Lab appears designed to solve that problem by converting users drawn in by morbid fascination into paying subscribers tracking their triglycerides.
Whether that works is another matter entirely.
From Gimmick to Glucose Panels
The new service, priced at $99, $199, and $299 annually across three tiers, offers integrated blood draws through a network of partner labs—Labcorp, Quest, and BioReference among them. The company's promotional materials cite access to over 4,800 locations, though the pricing page lists 4,200 sites across 49 states. (Minor discrepancies like that tend to surface when startups move quickly.) Users can also upload existing lab results and physician records, feeding data into what the company describes as an "AI health concierge."
The platform measures biomarkers spanning cardiometabolic health, inflammation, kidney and liver function, hormonal panels. The baseline $99 tier includes high-sensitivity C-reactive protein, comprehensive metabolic panels, lipid panels, HbA1c, among other markers. Step up to Foundation or Advanced, and you add apolipoprotein B, lipoprotein(a), fasting insulin, testosterone levels, DHEA, IGF-1—the full longevity enthusiast's shopping list.
Death Clock's original assessment remains at the core: a 29-question survey the company claims is trained on more than 1,200 longevity studies. But Life Lab introduces a "real-time life expectancy meter" that updates continuously as users log lab results, track screenings, report behavioral changes. The app spits out two numbers—a predicted death date and a "potential" later date achievable through optimized interventions.
That second number, one imagines, is where the sales pitch lives.
Undercutting the Competition, Sort Of
At $99, Death Clock's entry point sits well below some competitors. Function Health—which raised capital at a reported $2.5 billion valuation before later cutting its annual pricing to $365—offers twice-yearly testing of 100-plus biomarkers. Levels Labs has a Basic Panel at $99. Oura rolled out Health Panels as an add-on for ring users at the same price point. InsideTracker and Lifeforce operate membership models with varying tiers, some reaching well into the thousands annually.
Death Clock positions Life Lab as "democratizing concierge-level longevity services," shifting users from reactive care toward proactive prevention. The pitch targets a real gap: primary care physicians often focus on acute issues, while high-end longevity clinics analyze biomarkers to optimize healthspan but charge accordingly. Whether $99 annual testing can genuinely deliver concierge-quality insights—especially without insurance reimbursement—remains an open question. The longevity testing market hasn't yet proven it can achieve profitability at consumer-friendly price points while maintaining comprehensive panels.
Function Health's pricing adjustments late last year suggest the economics are tricky.
Who's Behind This?
Death Clock operates under the entity Most Days Inc. and lists backers including Freestyle Capital, Village Global, Harrison Metal, King River Capital, and Origin Ventures. The company hasn't disclosed funding amounts, valuation, or headcount. King River Capital confirmed its involvement on its 2026 portfolio page, but specific check sizes and investment dates remain private.
The company names a clinical board led by Dr. Tyler Johnson, with Dr. Marilyn Tan and Dr. Todd Dorfman also listed. Privacy policies indicate the platform uses generative AI processors—ChatGPT and Gemini among them—for data analysis, with lab results routed through entities including Vital and BioReference Laboratories under HIPAA authorization.
Franson, the founder, previously led Euclid Analytics, a spatial analytics company WeWork acquired in February 2019. (WeWork's subsequent implosion doesn't necessarily reflect on Euclid, though the association isn't exactly a résumé highlight these days.) In describing Life Lab, Franson emphasized the platform's training on longevity studies and its goal of providing "private doctor quality roadmap" analysis.
The Washington Post covered Death Clock last June in a column that described the 29-question experience and raised privacy concerns about the app's earlier iteration. At that time, the subscription cost $39 annually and the app included a "for fun" disclaimer—a hedge that Life Lab has notably dropped. The new clinical posture is more serious, though regulatory positioning and details about medical supervision remain somewhat vague in public materials.
A Crowded, Uncertain Field
The longevity testing market is getting noisy. Function Health made waves with its reported $2.5 billion valuation. Oura leveraged its existing ring user base to push into biomarker testing. Levels, known for continuous glucose monitoring, launched lab panels to expand beyond metabolic health. Death Clock now joins them, though it's entering from an unusual angle—viral app first, clinical credibility second.
A Forbes analysis from November explored whether blood testing startups can sustain profitability while offering comprehensive panels at accessible prices. Death Clock's $99 tier tests that thesis at the low end, though biomarker count and testing frequency vary across its three plans. App Store updates from December through early this year show continuous iteration: habit tracking, screening reminders, automated report updates. The platform's real-time life expectancy meter suggests a roadmap focused on engagement and personalization rather than one-time testing.
That's smart. One-off blood work doesn't build recurring revenue. Continuous tracking might.
The Pivot Problem
Whether Death Clock can scale from viral curiosity to durable health platform depends on execution, user retention, regulatory navigation. The company has name recognition—more than most health tech startups can claim. It also has a growing user base, with what it describes as "tens of thousands of paying users" alongside those million-plus downloads.
What it doesn't yet have is proof that morbid curiosity translates into sustained behavior change. Or that mass-market biomarker testing can actually deliver on the promise of extended healthspan, rather than simply generating data that most users won't act on.
Franson's bet is that people will pay to close the gap between knowing when they'll die and postponing that date. It's not the worst hypothesis. But the longevity space is littered with startups that assumed consumers would embrace quantified self-improvement, only to discover that tracking is easier than changing.
Death Clock has the hook. Now it needs to prove it can land the fish.
